News

Latest news

Hide mandatory notifications of trade

New Board after Annual General Meeting

Oslo 11.05.2012 - Bionor Pharma`s Shareholders Voted Industry Experts Steen Krøyer, Jerry Zeldis and Benedicte Fossum to its Board of Directors at Annual General Meeting

Bionor Pharma ASA announced today unanimously shareholder approval for
new and re-elected Board members to the Board of Directors, and members
to the Nomination Committee at the Company`s Ordinary
General Meeting 11 May.

Bionor Pharma is entering a dynamic phase with an extensive clinical program
leading towards phase III, partnering process and commercialization of existing
products. The Nomination Committee recommended the newly approved Board of
Directors in order to significantly strengthen the leadership that will help
guide the Company through the exciting and challenging time going forward.  The
Nomination Committee believes the new Board reflects the international clinical,
regulatory, and commercial experience needed as part of the preparations for a
partnering process ahead.

"This year we add extensive competence from big pharma to help lead our
company," said Lars H. Høie, MD, PhD, Chairman, Board of Directors, Bionor
Pharma.  "We're proud of our new Board of Directors and we're confident this
will help us put in place the international alliances we'll need to bring our
promising treatments to market."

The new Board members are joined by the following Board members who were not up for election:
- Lars H. Høie (Chairman)
- Marianne Furru (board member)
- Bjørn Fuglaas (board member)

The Newly Approved Board of Directors Are:

Steen Krøyer (elected as Deputy Chairman after a new CEO has taken his
position).  Mr. Krøyer is CEO at Bionor Pharma since September 2011.  Mr. Krøyer
has 35 years of experience in the pharmaceutical industry. Through leadership
positions in large companies such as Astra Zeneca and Astra, Chairman of smaller
companies and experience of business management in Europe, China and Asia, and
last year`s  experience as CEO of Bionor Pharma, Mr. Krøyer is considered to be
well suited as member of the Board of Directors as soon as his successor is in
place.

Jerome "Jerry"  Zeldis, MD.  Dr. Zeldis is CEO of Celgene Global Health and
Chief Medical Officer of Celgene Corporation, based in Summit, New Jersey. Dr.
Zeldis is an experienced global industry leader with a distinguished career at
one of the world's leading biopharmaceutical companies with operations in more
than 50 countries and products sold in more than 70 markets in the Americas,
Europe, and Asia Pacific regions. Ref. separate release 11 April 2012.

Benedicte Fossum   B.Sc. Veterinary Medicine.  One of the founders of Pharmaq
AS, the global leader in pharmaceuticals for aquaculture. Until January 2010,
Ms. Fossum was Director of Strategic Development, Legal Affairs and M&A within
Pharmaq AS. Professional experience from Alpharma Inc. (Regulatory Manager) and
the Norwegian Medicines Agency (Statens Legemiddelverk). Currently, Benedicte
Fossum is Director of the board of Navamedic ASA, Codfarmers ASA, ProBio ASA,
Probi AB, Smartfish AS, Foinco AS and Altaria AS.

Based on the above nominations, the new Board until Steen Krøyer's entry will
consist of:
- Lars H. Høie (Chairman)
- Bjorn Fuglaas (board member)
- Jerome Zeldis (board member)
- Benedicte Fossum (board member)
- Marianne Furru (board member)

Based on the above nominations, the new Board after Steen Krøyer's entry will
consist of:
- Lars H. Høie (Chairman)
- Steen Krøyer (Deputy Chairman)
- Jerome Zeldis (board member)
- Benedicte Fossum (board member)
- Marianne Furru (board member)

Shareholders also selected a new Nomination Committee:

Leader of the nomination committee:

Ivar Sigurd Eide (Leader, re-elected to the committee)

Members of the nomination committee:

Birger Sørensen EVP, Head of Vaccines, and Founder of the vaccine technology of
Bionor Pharma, is trained as physical chemist (M.Sc./Cand real) with mathematics
and biology as supporting subjects. Birger Sørensen is a major shareholder in
the Company.

Lars Helmer Enger (re-elected)


About Bionor Pharma ASA

Bionor Pharma is a biopharmaceutical, listed company based in Oslo, Norway. The
Company's investments in developing therapeutic vaccines exceed US$70 million.
Bionor's vaccines are based on the proprietary technology platform developed
following more than two decades of research on peptides. The vaccines are
designed to safely activate each person's immune system to combat viral
diseases.

The Company's lead investigational product, the HIV therapeutic vaccine Vacc-
4x, has in a completed phase IIb multinational (USA, Germany, UK, Spain and
Italy), placebo controlled, double-blind study, shown a statistically
significant reduction in viral load.

Bionor researchers believe that the 64 % reduction in viral load in patients who
received Vacc-4x in the phase IIb study  is a long-lasting viral control as a
result of the patient's immune system`s new ability to kill virus producing
cells, in contrast to the viral reduction obtained with daily conventional
medicine (antiretroviral therapy, ART).   Research shows that treatment with ART
is putting the virus producing cells into a resting state, from which they can
"wake up" even more than a decade later, and again start producing virus within
few weeks if patients go off ART.  Because most patients who are given ART are
known to stop taking it for various reasons (high costs, limited access,
development of resistance, and serious adverse events), Bionor believes Vacc-4x
could be a vital treatment option that can stabilize patients even when they
stop taking ART.

Bionor`s second HIV therapeutic vaccine, Vacc-C5 is planned to be ready for
first in man clinical trial 2Q 2012, and is developed to induce antibodies to
HIV that can reduce immune hyper activation associated with HIV infection.
Subsequent to the Vacc-C5 phase I/II trial, Bionor intends to combine Vacc-4x
with Vacc-C5, which could form the basis for both a therapeutic and a
preventative vaccine.

According to the UN organization UNAIDS, 34 million people were living with HIV
in 2010. Approximately three million new people are infected annually.
Pharmaceutical sales to treat HIV are US$ 10.6 billion (NOK 63 billion)
annually, and treatment cost per patient is approx. US$ 15,000 (NOK 90,000) per
year.

Only one out of six HIV infected patients globally are today provided with
treatment.

Pathways to market for HIV vaccines

Bionor researchers will investigate various independent pathways to market for
the HIV vaccine candidates Vacc-4x and Vacc-C5, through further clinical studies
starting this year:

1. Vacc-4x revaccination in patients who participated in the phase IIb study,
which aims to further reduce the viral load by killing of virus producing cells,
during periods where patients are not on ART.

2. Vacc-4x combined with Revlimid® (lenalidomide), in patients with a weakened
immune system which does not improve despite well controlled viral load by
treatment with ART.

3. Vacc-C5 clinical trial phase I/II, to document whether Vacc-C5 increases HIV
antibodies, subsequent Vacc-C5 in combination with Vacc-4x, with the aim of
eradicating HIV and thereby revolutionize HIV treatment.

Vaccines for other viral diseases

The Company's innovative technology platform is also well suited to develop
vaccines for other viral diseases, such as Influenza, HCV (Hepatitis C), HPV
(Human Papilloma Virus) and CMV (Cytomegalovirus).

All preclinical trials with Vacc-Flu (Universal Influenza vaccine) and Vacc-HCV
(Hepatitis C vaccine), including toxicology are planned to be finalized second
half 2012, thereby being ready to enter human clinical studies.

More information about Bionor Pharma, its research and products, is available at
www.bionorpharma.com.

This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act).
Vacc-4x is an investigational treatment that has not been approved for marketing
by any regulatory authority.

                                     # # #

Contacts:

Bionor Pharma ASA, Oslo: +47 23 01 09 60/Bionor Pharma laboratories:
+47 35 90 85 00
Lars H. Høie, MD, PhD, Chairman of the Board

USA Contact:
David Sheon 202 422-6999
dsheon@WHITECOATstrategies.com